{"id":129608,"date":"2022-05-18T09:41:40","date_gmt":"2022-05-18T13:41:40","guid":{"rendered":"https:\/\/44.250.171.167\/?p=129608"},"modified":"2022-10-06T03:23:01","modified_gmt":"2022-10-06T07:23:01","slug":"dr-lal-pathlabs-ltd-q4-fy22-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q4-fy22-earnings-conference-call-insights\/","title":{"rendered":"Dr Lal PathLabs Ltd Q4 FY22 Earnings Conference Call Insights"},"content":{"rendered":"<p><iframe loading=\"lazy\" title=\"Dr Lal PathLabs Ltd Q4 FY22 Earnings Concall\" width=\"500\" height=\"375\" src=\"https:\/\/www.youtube.com\/embed\/XGfFd6kLFCE?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p><strong>Key highlights from Dr Lal PathLabs Ltd (<a href=\"https:\/\/44.250.171.167\/symbol\/LALPATHLAB\/\">LALPATHLAB<\/a>) Q4 FY22 Earnings Concall<\/strong><\/p>\n<p><strong>Management Update:<\/strong><\/p>\n<ul>\n<li>LALPATHLAB said it saw significant shift towards direct-to-home business, with home collections now contributing nearly 12%, which used to be in the range of 5-6% during pre-COVID days. Also the company saw bundled packages continuing to rise.<\/li>\n<\/ul>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>Prakash Kapadia of Anived Portfolio asked why the growth was lower in organic non-COVID revenues for the company that was only up 4% YonY. Arvind Lal EC replied that in the month of January non-COVID was fairly low, mainly because of Omicron wave, however, the company exited on a good note in 4Q.<\/li>\n<\/ul>\n<ul>\n<li>Prakash Kapadia of Anived Portfolio also enquired about Suburban in terms of the milestone payout. Arvind Lal EC clarified that that piece is already closed now. It was linked to FY22 performance and the company is not paying anything over and above what it had paid in the first tranche, primarily because there were certain numbers, which were not achieved.<\/li>\n<\/ul>\n<ul>\n<li>Chirag Dagli from DSP Mutual asked about the profitability of the COVID business vs. the rest of the business for FY22. Arvind Lal EC said it\u2019s very difficult to segregate COVID profitability. COVID business gave a huge operating leverage and clearly INR396 crores of COVID business in FY22 definitely contributed to the bottom lines. But as this slides down, it will have impact on the overall number in FY23.<\/li>\n<\/ul>\n<ul>\n<li>Sriraam Rathi from BNP Paribas asked if the company could look at non-COVID business of INR160 -170 crores going forward. Ved Prakash CFO said the company is changing the recording of revenue from gross to net which will not be strictly comparable with INR170-180 crores that was pre-COVID. However, the company is trending much higher than what it used to do in the past.<\/li>\n<\/ul>\n<ul>\n<li>Sriraam Rathi from BNP Paribas also asked if the INR30 crores non-COVID revenue for Q4, would have been impacted to some extent by Omicron also. Ved Prakash CFO said that INR30 crores, plus the net revenue because this is not gross. There is a 20%, 25% kind of gross absorption.<\/li>\n<\/ul>\n<ul>\n<li>Sriraam Rathi from BNP Paribas asked if the 14-15% base business growth could be achieved from FY23. Arvind Lal EC said that the company feels that it is in the mid-teens range going forward. So LALPATHLAB believes it should be in place for that kind of growth.<\/li>\n<\/ul>\n<ul>\n<li>Sriraam Rathi from BNP Paribas asked if the margins that was lower in Q4 was impacted by Omicron only or something else. Ved Prakash Goel CFO said that one reason was largely the impact of Suburban consolidation and also the impact of Omicron on non-COVID business.<\/li>\n<\/ul>\n<ul>\n<li>Neha Manpuria from Bank of America asked about the non-COVID realization being down low-single digit YonY and if the trend is similar ex Suburban and including Suburban. Ved Prakash Goel CFO said that like to like revenue per patient is almost flat. So non-COVID utilization is almost same that the company used to have pre-COVID.<\/li>\n<\/ul>\n<ul>\n<li>Pooja Bhatia from Morgan Stanley asked that over the next 2-3 years, where does the company think margins could settle at. Arvind Lal EC replied that there is not scope to improve margins. But LALPATHLAB believes that margins would probably make what it used to have pre-COVID times.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q4 FY22 Earnings Concall Management Update: LALPATHLAB said it saw significant shift towards direct-to-home business, with home collections now contributing nearly 12%, which used to be in the range of 5-6% during pre-COVID days. Also the company saw bundled packages continuing to rise. Q&amp;A Highlights: Prakash Kapadia [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747,12],"tags":[8665,8157],"class_list":["post-129608","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","category-other-industries","tag-diagnostics","tag-healthcare"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":132298,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":129608,"position":0},"title":"Dr Lal PathLabs Ltd Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"August 3, 2022","format":false,"excerpt":"https:\/\/youtu.be\/GyHJJGLWdjg Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q1 FY23 Earnings Concall Management Update: LALPATHLAB said it clocked the highest quarterly non-COVID revenue of INR482 crore, a growth of 25% YoYs. Additionally, COVID revenue significantly declined by 91% from INR221 crore to INR21 crore in 1Q23. Q&A Highlights: Pooja\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":136294,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q2-fy23-earnings-conference-call-insights\/","url_meta":{"origin":129608,"position":1},"title":"Dr Lal PathLabs Ltd Q2 FY23 Earnings Conference Call Insights","author":"Praveen","date":"November 10, 2022","format":false,"excerpt":"https:\/\/youtu.be\/lAaNZKEvjOc Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q2 FY23 Earnings Concall Q&A Highlights: [00:16:43] Rahul Agarwal with Incred Capital enquired about 2Q23 performance according to the company\u2019s expectations. Arvind Lal EC said the company\u2019s opinion is that the performance is slightly in line with what it was doing\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":140051,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q3-fy23-earnings-conference-call-insights\/","url_meta":{"origin":129608,"position":2},"title":"Dr Lal PathLabs Ltd Q3 FY23 Earnings Conference Call Insights","author":"Praveen","date":"February 3, 2023","format":false,"excerpt":"Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q3 FY23 Earnings Concall Q&A Highlights: [00:12:28] Dheeresh Pathak from WhiteOak asked about the revenue and EBITDA for Suburban for 3Q23. C. A. Ved Prakash CFO said Suburban had revenue of INR37 crores, with INR35 crores from non-COVID and the rest from\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":145982,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q4-fy23-earnings-conference-call-insights\/","url_meta":{"origin":129608,"position":3},"title":"Dr Lal PathLabs Ltd Q4 FY23 Earnings Conference Call Insights","author":"Praveen","date":"May 12, 2023","format":false,"excerpt":"Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q4 FY23 Earnings Concall Q&A Highlights: [00:17:48] Rahul Agarwal from InCred Capital asked if 13-14% revenue growth can be seen next year, given the supportive base, low employee attrition, and faster growth outside Delhi NCR. Om Prakash MD said FY '23 was\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":131239,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-lalpathlab-q4-fy22-earnings-concall-transcript\/","url_meta":{"origin":129608,"position":4},"title":"Dr Lal PathLabs Ltd (LALPATHLAB) Q4 FY22 Earnings Concall Transcript","author":"IRS_INDIA","date":"May 17, 2022","format":false,"excerpt":"Dr Lal PathLabs Ltd (NSE: LALPATHLAB) Q4 FY22 Earnings Concall dated May. 17, 2022 Corporate Participants: Nishid Solanki\u00a0-- Arvind Lal\u00a0--\u00a0Executive Chairman Om Prakash Manchanda\u00a0--\u00a0Managing Director Uppiliappan Bharath\u00a0--\u00a0Chief Executive Officer Ved Prakash Goel\u00a0--\u00a0Chief Financial Officer Analysts: Prakash Kapadia\u00a0--\u00a0Anived Portfolio Managers -- Analyst Chirag Dagli\u00a0--\u00a0DSP Mutual Fund -- Analyst Sriraam Rathi\u00a0--\u00a0BNP Paribas\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"Earnings Conference Call Transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":127290,"url":"https:\/\/alphastreet.com\/india\/dr-lal-pathlabs-ltd-q3-fy22-earnings-conference-call-insights\/","url_meta":{"origin":129608,"position":5},"title":"Dr Lal PathLabs Ltd Q3 FY22 Earnings Conference Call Insights","author":"Praveen","date":"February 11, 2022","format":false,"excerpt":"https:\/\/www.youtube.com\/watch?v=q_lILVipT-E Key highlights from Dr Lal PathLabs Ltd (LALPATHLAB) Q3 FY22 Earnings Concall Management Update: The company is enhancing access of its services by strengthening omni-channel approach in cities and pursuing hub lab infrastructure in Tier 2 and Tier 3 towns. During 3Q22, the company successfully integrated AI in prostate\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/129608","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=129608"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/129608\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=129608"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=129608"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=129608"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}